Ranieyes 2.30mg Injection

Ranieyes 2.30mg Injection

Ranieyes 2.30mg Injection contains Ranibizumab (2.30mg), a recombinant humanized monoclonal antibody fragment that inhibits vascular endothelial growth factor A (VEGF-A). It is administered by a qualified ophthalmologist via intravitreal injection to treat retinal conditions associated with abnormal blood vessel growth and vascular leakage.

Key Features

• Contains Ranibizumab 2.30mg, an anti-VEGF biologic
• Administered via intravitreal injection by an ophthalmologist
• Inhibits abnormal blood vessel growth in the retina
• Used in the management of wet age-related macular degeneration and related retinal conditions
• Manufactured by Lupin Ltd

Key Ingredients

• Ranibizumab 2.30mg

Uses

Suitable for patients diagnosed with wet age-related macular degeneration, diabetic macular edema, or other retinal vascular conditions requiring anti-VEGF therapy, as prescribed by an ophthalmologist.

Directions for Use

To be administered only by a qualified ophthalmologist via intravitreal injection, strictly as prescribed. Not for self-administration.

Precautions

• To be administered only under ophthalmologist supervision in a sterile clinical setting
• Inform your doctor of any eye infections or inflammation before treatment
• Report any sudden vision changes, eye pain, or redness after injection immediately
• Not intended for use during pregnancy unless clearly advised by a doctor
• Keep away from children

Legal Disclaimer: The product is guaranteed to be 100% genuine. Product images are for illustrative purposes only.